PHVS · Pharvaris N.V. · Insider Trading

25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $33.00 to $33.0801. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $36.15 to $36.23. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Gift to charitable organization.

The reported price represents a weighted average sale price for shares sold in multiple transactions at prices ranging from $36.30 to $36.71 per share. The shares sold were acquired upon vesting of restricted stock units on various dates. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.62 to $38.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.04 to $38.65. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

GrayMatters Consulting B.V., an entity controlled by Dr. Lesage

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.26 to $38.89. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

The reported price represents a weighted average sale price for shares sold in multiple transactions at prices ranging from $39.2150 to $39.27 per share. The shares sold were acquired upon vesting of restricted stock units on various dates. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.00 to $38.35. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled sale from 10b5-1 trading plan.

100% of the option vest on the 12-month anniversary.

25% of the option vested on November 15, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.175 to $38.43. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The shares were acquired upon vesting of restricted stock units and sold pursuant to a Rule 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.69 to $40.39. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $39.00 to $39.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.

This is a scheduled exercise and sale from 10b5-1 trading plan.

Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $40.00 to $40.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.00 to $38.90. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.21 to $37.83. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

This is a scheduled exercise and sale from 10b5-1 trading plan.

The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $40.50 to $40.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

The shares were acquired upon vesting of restricted stock units and sold pursuant to a Rule 10b5-1 trading plan.